TYK2
ENSG00000105397
Target class
Kinase
Chromosome
19
Approved drugs
7
Clinical candidates (approved and in development)
14
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 14
- Chemical probe available
- Yes
- Other names
- JTK1
- Target name
- TYK2
- Gene name
- Tyrosine kinase 2
- Gene symbol
- TYK2
- Protein name
- Non-receptor tyrosine-protein kinase TYK2 (EC 2.7.10.2)
- Gene biotype
- Protein coding
- Gene family
- FERM domain containing|Jak family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 100.47
- Tissue specificity (Gini)
- 0.298
- Tissue specificity (tau)
- 0.643
- KEGG gene identifiers
- hsa:7297
- Protein interaction confidence
- 0.853047
- Protein interaction partners
- 107
- R-HSA-1059683
- R-HSA-110056
- R-HSA-112411
- R-HSA-449836
- R-HSA-6783783
- R-HSA-6785807
- R-HSA-6788467
- R-HSA-8854691
- R-HSA-8984722
- R-HSA-9020591
- R-HSA-9020933
- R-HSA-9020956
- R-HSA-909733
- R-HSA-912694
- R-HSA-9674555
- R-HSA-9679191
- R-HSA-9705462
- R-HSA-9705671
- R-HSA-9725370
- R-HSA-9833109
- R-HSA-9958825
- End position
- 10380608
- Start position
- 10350528
- Chromosome
- 19
- Strand
- Reverse
- Cytosol
- Tissue specificity (tau)
- 0.642743
- Expression inequality (Gini)
- 0.298022
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 100.47
- Spleen
- 95
- Whole Blood
- 78.64
- Lung
- 65.86
- Nerve - Tibial
- 65.39
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes100.47
- Spleen95
- Whole Blood78.64
- Lung65.86
- Nerve - Tibial65.39
- Thyroid61.37
- Cervix - Endocervix58.88
- Ovary55.75
- Brain - Cerebellum53.94
- Pituitary53.24
- Uterus52.79
- Cervix - Ectocervix50.28
- Prostate50.07
- Small Intestine - Terminal Ileum49.12
- Brain - Cerebellar Hemisphere48.47
- Fallopian Tube48.43
- Adipose - Subcutaneous44.62
- Breast - Mammary Tissue44.6
- Cells - Cultured fibroblasts42.65
- Bladder41.84
- Vagina41.23
- Skin - Sun Exposed (Lower leg)40.34
- Minor Salivary Gland40.02
- Skin - Not Sun Exposed (Suprapubic)38.3
- Adipose - Visceral (Omentum)36.82
And 29 more, listed on the interactive page.
- GO:0006468
- GO:0007259
- GO:0019221
- GO:0035722
- GO:0038155
- GO:0060333
- GO:0060337
- GO:0140105
- GO:1900182
- GO:0005634
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0009898
- GO:0019897
- GO:0031234
- GO:0070062
- GO:0004713
- GO:0004715
- GO:0005131
- GO:0005515
Related records
Trials (574)
- 3T Therapy in the Treatment of MDA5-positive Dermatomyositis
- 68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage
- A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
- A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
- A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
- A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
- A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
- A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
- A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
- A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
- A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
- A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
- A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
- A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis
- A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
- A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
- A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Drugs (18)
- Brepocitinib Tyrosine-protein kinase TYK2 inhibitor
- Cerdulatinib Tyrosine-protein kinase TYK2 inhibitor
- Cravacitinib Tyrosine-protein kinase TYK2 negative allosteric modulator
- Delgocitinib Janus Kinase (JAK) inhibitor
- Deucravacitinib Tyrosine-protein kinase TYK2 negative allosteric modulator
- Deuruxolitinib phosphate Tyrosine-protein kinase TYK2 inhibitor
- Filgotinib Tyrosine-protein kinase TYK2 inhibitor
- Filgotinib maleate Tyrosine-protein kinase TYK2 inhibitor
- Gusacitinib Janus Kinase (JAK) inhibitor
- Izencitinib Janus Kinase (JAK) inhibitor
- Nezulcitinib Janus Kinase (JAK) inhibitor
- Peficitinib Janus Kinase (JAK) inhibitor
- Ropsacitinib Tyrosine-protein kinase TYK2 inhibitor
- Ruxolitinib Tyrosine-protein kinase TYK2 inhibitor
- Tofacitinib Janus Kinase (JAK) inhibitor
- Tofacitinib citrate Janus Kinase (JAK) inhibitor
- Upadacitinib Tyrosine-protein kinase TYK2 inhibitor
- Upadacitinib hemihydrate Tyrosine-protein kinase TYK2 inhibitor